• Monika EngelhardtEmail author
  • Stefanie Ajayi
  • Heike Reinhardt
  • Stefan Jürgen Müller
  • Sandra Maria Dold
  • Ralph Wäsch
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 212)


Pomalidomide (originally CC-4047 or 3-amino-thalidomide) is a derivative of thalidomide that is antiangiogenic and also acts as immunomodulatory. Pomalidomide, the recent immunomodulatory agent (IMiD), has shown substantial in vitro antiproliferative and proapoptotic effects. In vivo studies have suggested limited cross-resistance between lenalidomide and pomalidomide. Moreover, pomalidomide achieved very convincing responses in relapsed and refractory multiple myeloma (RRMM) patients, including those, who are refractory to both lenalidomide and bortezomib. Since pomalidomide plus low-dose dexamethasone has shown better responses, progression-free survival (PFS) and overall survival (OS) than high-dose dexamethasone or pomalidomide alone, subsequent trials have pursued or are still investigating pomalidomide triplet combinations, using cyclophosphamide or other novel agents, such as proteasome inhibitors (PI: bortezomib, carfilzomib) or antibodies, like elotuzumab or daratumumab. Pomalidomide has also been assessed in AL amyloidosis, MPNs (myelofibrosis [MF]), Waldenstrom’s macroglobulinemia, solid tumors (sarcoma, lung cancer), or HIV, and—for AL amyloidosis and MF—has already been proven to be remarkably active. Due to its potency, pomalidomide was approved for RRMM by the US Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) in 2013 and for drug combination with low-dose dexamethasone in 2015. In June 2017, the FDA further expanded approval for pomalidomide in combination with daratumumab and low-dose dexamethasone for patients with RRMM.


Pomalidomide Multiple myeloma Relapsed/refractory disease Therapy options 


  1. Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S (2016) Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 127(21):2561–2568CrossRefPubMedGoogle Scholar
  2. Bringhen S, Magarotto V, Liberati M et al (2016) A multicenter, open label phase I/II study of carfilzomib, pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (MM) patients [Oral]. In: Oral presented at: 58th annual meeting and exposition of the American Society of Hematology (ASH); December 3–6, 2016; San Diego, CA, USAGoogle Scholar
  3. Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S (2017) Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 130(8):974–981CrossRefPubMedPubMedCentralGoogle Scholar
  4. D’Amato R, Lentzsch S, Anderson KC, Rogers MS (2001) Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol 28:597–601CrossRefPubMedGoogle Scholar
  5. Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF (2015) Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica 100(10):1327–1333CrossRefPubMedPubMedCentralGoogle Scholar
  6. Geyer HL, Viggiano RW, Lacy MQ, Witzig TE, Leslie KO, Mikhael JR, Stewart K (2011) Acute lung toxicity related to pomalidomide. Chest 140:529–533CrossRefPubMedGoogle Scholar
  7. Gandhi AK, Kang J, Havens CG et al (2014) Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol 164(6):811–821CrossRefPubMedGoogle Scholar
  8. Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT, Nahar S, Mimura N, Fabre C, Raje N, Munshi N, Richardson P, Anderson KC (2010) Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116:3227–3237CrossRefPubMedPubMedCentralGoogle Scholar
  9. IMNOVID®: summary of product characteristics; Celgene,; last revised September 2016
  10. Jakubowiak AJ, Rosenbaum CA, Stephens L et al (2017) Final results of phase (PH) 1/2 study of carfilzomib; pomalidomide; and dexamethasone (KPD) in patients (PTS) with relapsed/refractory multiple myeloma (RRMM): a multi-center MMRC study [Meeting Abstract]. In: Presented at: 22nd Congress of the European Hematology Association (EHA), June 22–25, 2017, Madrid, Spain. Poster#P680Google Scholar
  11. Kortüm KM, Zhu YX, Shi CX, Jedlowski P, Stewart AK (2015) Cereblon binding molecules in multiple myeloma. Blood Rev 29:329–334CrossRefPubMedGoogle Scholar
  12. Lacy MQ, Kumar SK, LaPlant BR, Laumann K, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Russell S, Dingli D, Zeldenrust SR, Fonseca R, Bergsagel PL, Stewart K, Roy V, Sher T, Chanan-Khan A, Reeder C, Rajkumar SV, Mikhael JR (2012) Pomalidomide plus low-dose dexamethasone (Pom/Dex) in relapsed myeloma: long term follow up and factors predicting outcome in 345 patients. Blood 120:201Google Scholar
  13. Lacy MQ (2013) “IM iD” eally treating multiple myeloma. Blood 121:1926–1928CrossRefPubMedGoogle Scholar
  14. Lacy MQ, LaPlant BR, Laumann KM et al (2014) Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide refractory multiple myeloma. ASH Annual Meeting. Abstract 304. Presented December 8, 2014Google Scholar
  15. Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Fermand JP, Avet-Loiseau H, Facon T (2013) Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009–02. Blood 121:1968–1975CrossRefGoogle Scholar
  16. Lopez-Girona A, Mendy D, Ito T et al (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26(11):2326–2335CrossRefPubMedPubMedCentralGoogle Scholar
  17. Matous J, Siegel DS, Lonial S et al (2014) MM-008: a phase 1 trial evaluating pharmacokinetics and tolerability of pomalidomide + low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed or refractory multiple myeloma and renal impairment [poster]. In: Poster presented at: 56th annual meeting and exposition of the American Society of hematology (ASH); December 6–9, 2014; San Francisco, CA, USAGoogle Scholar
  18. Mitsiades CS, Chen-Kiang S (2013) Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. Crit Rev Oncol Hematol 88(Suppl 1):S5–S13CrossRefPubMedGoogle Scholar
  19. Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G (2017) A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood 129(15):2120–2123CrossRefPubMedGoogle Scholar
  20. Ramasamy K, Dimopoulos MA, Van de Donk NWCJ, et al. (2015) Safety of treatment (Tx) with pomalidomide (POM) and low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) and renal impairment (RI), including those on dialysis [meeting abstract]. In: Presented at: 57th annual meeting and exposition of the American Society of Hematology (ASH); December 5–8, 2015, Orlando FL, USA. Abstract# 374Google Scholar
  21. Raza S, Safyan RA, Lentzsch S (2017) Immunomodulatory drugs (IMiDs) in multiple myeloma. Curr Cancer Drug Targets 17(9):846–857PubMedGoogle Scholar
  22. Ríos-Tamayo R, Martín-García A, Alarcón-Payer C, Sánchez-Rodríguez D, del Valle Díaz de la Guardia AM, García Collado CG, Jiménez Morales A, Jurado Chacón M, Cabeza Barrera J (2017) Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. Drug Des Devel Ther 11:2399–2408Google Scholar
  23. Richardson P, Baz R et al (2009) A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. Blood 114:301CrossRefGoogle Scholar
  24. Richardson P, Jakubowiak A, Bahlis NJ, Siegel DS, Chen CI, Chen M, Zaki M, Larkins G, Anderson K (2012) Treatment outcomes with pomalidomide (POM) in combination with low-dose dexamethasone (LoDex) in patients with relapsed and refractory multiple myeloma (RRMM) and del(17p13) and/or t(4;14) (p16;q32) cytogenetic abnormalities who have received prior therapy with lenalidomide (LEN) and bortezomib (BORT). Blood 120:4053Google Scholar
  25. Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC (2013) Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 121:1961–1967CrossRefPubMedPubMedCentralGoogle Scholar
  26. Richardson PG, Bensmaine A, Doerr T, Wang J, Zaki M (2015) MM-007: a phase 3 trial comparing the efficacy and safety of pomalidomide (POM) bortezomib (BORT) and low-dose-dexamethasone (LoDEX[PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM) [Poster]. In: Poster presented at: 2015 annual meeting of the American Society of Clinical Oncology (ASCO); May 29–June 2, 2015; Chicago, IL USAGoogle Scholar
  27. San Miguel J, Weisel K, Moreau P et al (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14(11):1055–1066CrossRefGoogle Scholar
  28. Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi C-X, Bruins L, Schmidt J, Ahmann G, Kumar SK, Rajkumar SV, Mikhael JR, Roy V, LaPlant BR, Laumann K, Barlogie B, Shaughnessy JD Jr, Fonseca R, Bergsagel L, Lacy MQ, Stewart K (2012) Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. Blood 120:194Google Scholar
  29. Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV (2015) Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 125(26):4042–4051CrossRefPubMedPubMedCentralGoogle Scholar
  30. Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG (2015) Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 126(20):2284–2290CrossRefPubMedPubMedCentralGoogle Scholar
  31. Siegel DS, Richardson PG, Baz R, Chen M, Zaki M, Anderson KC (2012) Pomalidomide with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma: impact of renal function on patient outcomes [Poster]. In: Poster presented at: 54th annual meeting of the American Society of Hematology (ASH); December 8–11, 2012, Atlanta, GA, USAGoogle Scholar
  32. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Bladé J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127(24):2955–2962CrossRefPubMedPubMedCentralGoogle Scholar
  33. Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M (2017) CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. Br J Haematol 179(1):36–49CrossRefPubMedGoogle Scholar
  34. Wäsch R, Jakob T, Technau K, Finke J, Engelhardt M (2012) Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation. Ann Hematol 91:287–289CrossRefPubMedGoogle Scholar
  35. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118:4771–4779CrossRefPubMedPubMedCentralGoogle Scholar
  36. Zhu YX, Kortuem KM, Stewart AK (2013) Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 54(4):683–687CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Monika Engelhardt
    • 1
    • 2
    Email author
  • Stefanie Ajayi
    • 1
    • 2
  • Heike Reinhardt
    • 1
  • Stefan Jürgen Müller
    • 1
  • Sandra Maria Dold
    • 1
  • Ralph Wäsch
    • 1
    • 2
  1. 1.Hematology and Oncology, University of FreiburgFreiburgGermany
  2. 2.Comprehensive Cancer Center Freiburg (CCCF)FreiburgGermany

Personalised recommendations